natgillin/translations-raw huggingface dataset:
The film-coated tablets must be taken orally, swallowed with a sufficient quantity of liquid and may be taken with or without food.
Tablete se zaužijejo peroralno z dovolj tekočine.
The daily dose is administered in two equally divided doses.
Jemlje se jih lahko s hrano ali brez nje.
• Monotherapy Adults and adolescents from 16 years of age
Dnevni odmerek se daje razdeljen v dva enaka odmerka. • Monoterapija Odrasli in mladostniki od 16. leta starosti
• Add-on therapy Adults (≥ 18 years) and adolescents (12 to 17 years) weighing 50 kg or more
• Dopolnilno zdravljenje Odrasli (≥ 18 let) in mladostniki (od 12 do 17 let), težki 50 kg in več.
2 Adjustment of the dose is recommended in elderly patients with compromised renal function (see “ Patients with renal impairment ” below).
Pri starejših bolnikih z okvarjenim delovanjem ledvic je priporočljiva prilagoditev odmerka (glejte spodaj “ Bolniki z ledvično okvaro ”).
Children aged 4 to 11 years and adolescents (12 to 17 years) weighing less than 50 kg
Otroci, stari med 4. in 11. letom, in mladostniki (od 12 do 17 let), težki manj kot 50 kg
The initial therapeutic dose is 10 mg/ kg twice daily.
2 Začetni terapevtski odmerek je 10 mg/ kg dvakrat na dan.
Depending upon the clinical response and tolerability, the dose can be increased up to 30 mg/ kg twice daily.
Odmerek se lahko poveča do 30 mg/ kg dvakrat na dan glede na klinični odziv in toleranco.
Dose changes should not exceed increases or decreases of 10 mg/ kg twice daily every two weeks.
Na vsaka 2 tedna lahko odmerek povečamo ali zmanjšamo za ne več kot 10 mg/ kg dvakrat na dan.
Dosage in children 50 kg or greater is the same as in adults.
Pri otrocih, ki so težki 50 kg ali več, je odmerjanje enako kot pri odraslih.
The physician should prescribe the most appropriate pharmaceutical form and strength according to weight and dose.
Glede na telesno maso in odmerek mora zdravnik predpisati najbolj ustrezno farmacevtsko obliko ali jakost.
Dosage recommendations for children and adolescents:
Priporočeno odmerjanje za otroke in mladostnike:
Weight
telesna masa
10 mg/ kg twice daily
10 mg/ kg dvakrat na dan
30 mg/ kg twice daily
30 mg/ kg dvakrat na dan
15 kg (1) 20 kg (1) 25 kg From 50 kg (2) (1)
15 kg (1) 20 kg (1) 25 kg nad 50 kg (2) (1)
150 mg twice daily 200 mg twice daily 250 mg twice daily 500 mg twice daily
150 mg dvakrat na dan 200 mg dvakrat na dan 250 mg dvakrat na dan 500 mg dvakrat na dan
450 mg twice daily 600 mg twice daily 750 mg twice daily 1500 mg twice daily
450 mg dvakrat na dan 600 mg dvakrat na dan 750 mg dvakrat na dan 1500 mg dvakrat na dan
Children 20 kg or less should preferably start the treatment with Keppra 100 mg/ ml oral solution.
Pri otroci, težkih 20 kg ali manj, je boljše začeti terapijo z zdravilom Keppra 100 mg/ ml peroralna raztopina.
(2) Dosage in children and adolescents 50 kg or more is the same as in adults.
(2) Pri otrocih in mladostnikih, težkih 50 kg ali več, je odmerjanje enako kot pri odraslih.
Infants and children less than 4 years
Doječki in otroci, mlajši od 4 let Pri otrocih, mlajših od 4 let, zdravila Keppra ni priporočljivo uporabljati, ker ni dovolj podatkov glede varnosti in učinkovitosti (glejte poglavje 5. 2).
To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in ml/ min is needed.
Za uporabo te tabele je potrebno predhodno oceniti bolnikov očistek kreatinina (CLcr) v ml/ min.
The CLcr in ml/ min may be estimated from serum creatinine (mg/ dl) determination using the following formula:
CLcr v ml/ min je mogoče oceniti iz koncentracije kreatinina v serumu (mg/ dl) po formuli:
[140-age (years)] x weight (kg) CLcr (ml/ min) = ----------------------------------------- 72 x serum creatinine (mg/ dl)
[140 – starost (leta)] x masa (kg) CLcr (ml/ min) = ------------------------------------------------------------- (x 0, 85 za ženske) 72 x koncentracija kreatinina v serumu (mg/ dl)
Then CLcr is adjusted for body surface area (BSA) as follows:
CLcr je prilagojen na telesno površino (BSA - » body surface area «) na sledeč način:
3 Dosing adjustment for adult patients with impaired renal function
Prilagoditev odmerjanja pri odraslih bolnikih z okvarjenim delovanjem ledvic
Group
odmerjanje in pogostnost skupina
Creatinine clearance (ml/ min/ 1.73m2)
očistek kreatinina (ml/ min/ 1, 73m2)
Normal Mild Moderate Severe End-stage renal disease patients Undergoing dialysis (1)
normalno delovanje ledvic blaga ledvična okvara zmerna ledvična okvara huda ledvična okvara
> 80 50-79 30-49 < 30 -
> 80 50– 79 30– 49 < 30
500 to 1,500 mg twice daily 500 to 1,000 mg twice daily 250 to 750 mg twice daily 250 to 500 mg twice daily 500 to 1,000 mg once daily (2)
500 do 1. 500 mg dvakrat na dan 500 do 1. 000 mg dvakrat na dan 250 do 750 mg dvakrat na dan 250 do 500 mg dvakrat na dan 500 do 1. 000 mg enkrat na dan( 2)
(1) A 750 mg loading dose is recommended on the first day of treatment with levetiracetam.
Prvi dan zdravljenja z levetiracetamom je priporočljiv začetni odmerek 750 mg.
For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function.
3 Pri otrocih z ledvično okvaro je treba odmerek levetiracetama prilagoditi glede na delovanje ledvic, kajti z njihovim delovanjem je povezan tudi očistek levetiracetama.
Therefore a 50% reduction of the daily maintenance dose is recommended when the creatinine clearance is < 70 ml/ min.
Če je očistek kreatinina < 70 ml/ min, je priporočljivo zmanjšati dnevni vzdrževalni odmerek za 50%.
Hypersensitivity to levetiracetam or other pyrrolidone derivatives or any of the excipients.
Preobčutljivost za levetiracetam, druge pirolidonske derivate ali katerokoli pomožno snov.
500 mg decreases twice daily every two to four weeks; in children: dose decrease should not exceed 10 mg/ kg twice daily every two weeks).
Če je treba zdravljenje s Keppro prekiniti, je skladno s trenutno klinično prakso, priporočljivo zdravljenje opustiti postopno (npr. pri odraslih: zmanjševanje odmerka za 500 mg dvakrat na dan na vsaka dva tedna do štiri tedne; pri otrocih: zmanjšanje odmerka ne sme preseči 10 mg/ kg dvakrat na dan vsaka dva tedna).
An increase in seizure frequency of more than 25% was reported in 14% of levetiracetam treated adult and paediatric patients with partial onset seizures, whereas it was reported in 26% and 21% of placebo treated adult and paediatric patients, respectively.
O več kot 25% povečanju pogostnosti napadov so poročali pri 14% odraslih bolnikov in otrok z napadi parcialnega izvora, zdravljenih z levetiracetamom, in pri 26% odraslih bolnikov ter pri 21% otrok, ki so dobivali placebo.
When Keppra was used to treat primary generalised tonic-clonic seizures in adults and adolescents with idiopathic generalised epilepsy, there was no effect on the frequency of absences.
Pri uporabi Keppre za zdravljenje primarno generaliziranih tonično- kloničnih napadov pri odraslih in mladostnikih z idiopatsko generalizirano epilepsijo, ni bilo vpliva na pogostnost pojava absenc.
The administration of Keppra to patients with renal impairment may require dose adjustment.
Pri bolnikih z ledvično okvaro je lahko pri uporabi Keppre potrebna prilagoditev odmerka.
In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection (see section 4.2).
Pri bolnikih z okvarjenim delovanjem jeter je pred izbiro odmerka priporočljivo oceniti delovanje ledvic (glejte poglavje 4. 2).
A meta-analysis of randomized placebo-controlled trials of anti-epileptic drugs has shown a small increased risk of suicidal thoughts and behaviour.
Majhno povečanje tveganja za pojav samomorilnega razmišljanja in vedenja je pokazala tudi metaanaliza randomiziranih, s placebom nadzorovanih kliničnih preskušanj antiepileptikov.
Therefore patients should be monitored for signs of depression and/ or suicidal ideation and behaviours and appropriate treatment should be considered.
Zato je treba bolnike med zdravljenjem nadzirati glede znakov depresije in/ ali samomorilnega razmišljanja in vedenja ter razmisliti o ustreznem zdravljenju.
Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/ or suicidal ideation or behaviour emerge.
Bolnikom (in skrbnikom bolnikov) je treba svetovati, naj poiščejo zdravniško pomoč, če se pojavijo znaki depresije in/ ali samomorilnega razmišljanja in vedenja.
Pre-marketing data from clinical studies conducted in adults indicate that Keppra did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of Keppra.
Predmarketinški podatki iz kliničnih študij izvedenih pri odraslih kažejo, da Keppra ne vpliva na serumsko koncentracijo ostalih protiepileptičnih zdravil (fenitoina, karbamazepina, valprojske kisline, fenobarbitala, lamotrigina, gabapentina in primidona), in da ta protiepileptična zdravila ne vplivajo na farmakokinetiko Keppre.
As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/ kg/ day levetiracetam.
Tako kot pri odraslih, tudi pri otrocih, ki so prejemali do 60 mg/ kg/ dan levetiracetama, ni jasnih dokazov o klinično značilnem medsebojnem delovanju z zdravili.
A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with orally administered levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate.
Retrospektivna ocena o farmakokinetičnih interakcijah pri otrocih in mladostnikih z epilepsijo (od 4 do 17 let) je potrdila, da dopolnilna terapija s peroralno vzetim levetiracetamom ni vplivala na koncentracije v serumu v stanju dinamičnega ravnovesja pri sočasnem dajanju karbamazepina in
However, data suggested a 22% higher levetiracetam clearance in children taking enzyme- inducing antiepileptic medicinal products.
Vendar pa podatki nakazujejo, da je pri otrocih, kateri jemljejo protiepileptična zdravila, ki inducirajo encime, povečan očistek levetiracetama za 22%.
Dosage adjustment is not required.
Prilagoditev odmerjanja ni potrebna.
Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite but not of levetiracetam.
Ugotovili so, da probenecid (500 mg štirikrat na dan), ki blokira ledvično tubularno sekrecijo, zavre ledvični očistek primarnega presnovka, ne pa levetiracetama.
It is expected that other medicinal products excreted by active tubular secretion could also reduce the renal clearance of the metabolite.
Pričakovati je, da tudi druga zdravila, ki se izločajo z aktivno tubularno sekrecijo, lahko zmanjšajo ledvični očistek tega presnovka.
NSAIDs, sulfonamides and methotrexate, is unknown.
Učinka levetiracetama na probenecid niso raziskali, prav tako ni znan njegov učinek na druga zdravila, ki se izločajo z aktivno sekrecijo, npr. na NSAID, sulfonamide in metotreksat.
Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl- estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified.
Levetiracetam v odmerku 1. 000 mg na dan ni vplival na farmakokinetiko peroralnih kontraceptivov (etinilestradiola in levonorgestrela); endokrini parametri (luteinizirajoči hormon in progesteron) se niso spremenili.
Levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified.
Levetiracetam v odmerku 2. 000 mg na dan ni vplival na farmakokinetiko digoksina in varfarina; protrombinski čas se ni spremenil.
No data on the influence of antacids on the absorption of levetiracetam are available.
Hrana ne vpliva na obseg absorpcije levetiracetama, rahlo pa zmanjša hitrost absorpcije.
The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced.
4. 6 Nosečnost in dojenje
There are no adequate data from the use of Keppra in pregnant women.
O uporabi Keppre pri nosečnicah ni dovolj podatkov.
Studies in animals have shown reproductive toxicity (see section 5.3).
Študije na živalih so pokazale reprodukcijsko toksičnost (glejte poglavje 5. 3).
The potential risk for human is unknown.
Potencialno tveganje za ljudi ni znano.
Keppra should not be used during pregnancy unless clearly necessary.
Keppre se med nosečnostjo ne sme uporabljati, razen če ni nedvomno potrebna.
As with other antiepileptic drugs, physiological changes during pregnancy may affect levetiracetam concentration.
Kot pri drugih antiepileptikih, lahko fiziološke spremembe med nosečnostjo vplivajo na koncentracijo levetiracetama.
This decrease is more pronounced during the third trimester (up to 60% of baseline concentration before pregnancy).
To zmanjšanje koncentracije je bolj izrazito v času tretjega trimesečja (do 60% glede na običajno koncentracijo pred nosečnostjo).
Therefore, breast-feeding is not recommended.
Levetiracetam se izloča v materino mleko, zato dojenje ni priporočljivo.
However, if levetiracetam treatment is needed during breastfeeding, the benefit/ risk of the treatment should be weighed considering the importance of breastfeeding.
Če je zdravljenje z levetiracetamom v obdobju dojenja potrebno, se mora pretehtati razmerje med koristjo in tveganjem zdravljenja glede na pomembnost dojenja.
Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose 5 increase.
Pri nekaterih bolnikih se lahko zaradi različne individualne občutljivosti predvsem na začetku zdravljenja ali po povečanju odmerka pojavi zaspanost ali drugi simptomi povezani s centralnim živčnim sistemom.
Therefore, caution is recommended in those patients when performing skilled tasks, e. g. driving vehicles or operating machinery.
Ti bolniki morajo biti zato previdni pri izvajanju zahtevnih opravil, npr. pri vožnji vozil ali upravljanju strojev.
Pooled safety data from clinical studies conducted with Keppra oral formulations in adult patients with partial onset seizures showed that 46.4% of the patients in the Keppra group and 42.2% of the patients in the placebo group experienced undesirable effects.
Kumulativni varnostni podatki iz kliničnih študij izvedenih pri odraslih bolnikih z napadi parcialnega izvora, ki so prejemali peroralne oblike zdravila Keppra, kažejo, da so se neželeni učinki pojavili pri 46, 4% bolnikov, ki so prejemali Keppro, in 42, 2% bolnikov, ki so prejemali placebo.
Serious undesirable effects were experienced in 2.4% of the patients in the Keppra and 2.0% of the patients in the placebo groups.
Resni neželeni učinki so se pojavili pri 2, 4% bolnikov, ki so prejemali Keppro, in pri 2, 0% tistih, ki so prejemali placebo.
The most commonly reported undesirable effects were somnolence, asthenia and dizziness.
Najpogosteje opisani neželeni učinki so bili zaspanost, astenija in omotica.
In the pooled safety analysis, there was no clear dose-response relationship but incidence and severity of the central nervous system related undesirable effects decreased over time.
Kljub temu, da v kumulativni varnostni analizi niso ugotovili jasne povezave med odmerkom in odzivom, sta se incidenca in resnost neželenih učinkov na centralni živčni sistem sčasoma zmanjšala.
In monotherapy 49.8% of the subjects experienced at least one drug related undesirable effect.
5 Pri monoterapiji je 49, 8% bolnikov doživelo vsaj en neželeni učinek, povezan z zdravilom.
The most frequently reported undesirable effects were fatigue and somnolence.
Neželena učinka, o katerih so najpogosteje poročali, sta bila utrujenost in somnolenca.
A study conducted in paediatric patients (4 to 16 years) with partial onset seizures showed that 55.4% of the patients in the Keppra group and 40.2% of the patients in the placebo group experienced undesirable effects.
Študija, ki je bila izvedena pri otrocih (od 4 let do 16 let) z napadi parcialnega izvora, je pokazala, da je 55, 4% bolnikov, ki so prejemali Keppro, in 40, 2% bolnikov, ki so prejemali placebo, imelo neželene učinke.
Serious undesirable effects were experienced in 0.0% of the patients in the Keppra group and 1.0% of the patients in the placebo group.
0, 0% bolnikov, ki so prejemali Keppro, in 1, 0% bolnikov, ki so prejemali placebo, je imelo resne neželene učinke.
The most commonly reported undesirable effects were somnolence, hostility, nervousness, emotional lability, agitation, anorexia, asthenia and headache in the paediatric population.
Najpogostejši neželeni učinki, o katerih so poročali v populaciji otrok, so zaspanost, sovražnost, nervoza, čustvena labilnost, agitiranost, anoreksija, astenija in glavobol.
Safety results in paediatric patients were consistent with the safety profile of levetiracetam in adults except for behavioural and psychiatric adverse events which were more common in children than in adults (38.6% versus 18.6%).
Rezulati glede varnosti pri otrocih so bili skladni s profilom varnosti levetiracetama pri odraslih, z izjemo vedenjskih in psihiatričnih neželenih dogodkov, ki so bili bolj pogosti pri otrocih kot odraslih (38, 6% proti 18, 6%).
However, the relative risk was similar in children as compared to adults.
Relativno tveganje pri otrocih je bilo podobno kot pri odraslih.
A study conducted in adults and adolescents with myoclonic seizures (12 to 65 years) showed that 33.3% of the patients in the Keppra group and 30.0% of the patients in the placebo group experienced undesirable effects that were judged to be related to treatment.
Študija, ki je bila izvedena pri odraslih in mladostnikih z miokloničnimi napadi (od 12 do 65 let) je pokazala, da je 33, 3% bolnikov, ki so prejemali Keppro, in 30, 0% bolnikov, ki so prejemali placebo, imelo neželene učinke, za katere so presodili, da so povezani z zdravljenjem.
The most commonly reported undesirable effects were headache and somnolence.
Najpogosteje opisani neželeni učinki so bili glavobol in somnolenca.
The incidence of undesirable effects in patients with myoclonic seizures was lower than that in adult patients with partial onset seizures (33.3% versus 46.4%).
Pogostnost neželenih učinkov pri bolnikih z miokloničnimi napadi je bila manjša kot pri odraslih bolnikih z napadi parcialnega izvora (33, 3% proti 46, 4%).
A study conducted in adults and children (4 to 65 years) with idiopathic generalised epilepsy with primary generalised tonic-clonic seizures showed that 39.2% of the patients in the Keppra group and 29.8% of the patients in the placebo group experienced undesirable effects that were judged to be related to treatment.
Študija, ki je bila izvedena pri odraslih in otrocih (od 4 do 65 let) z idiopatsko generalizirano epilepsijo s primarno generaliziranimi tonično- kloničnimi napadi, je pokazala, da je 39, 2% bolnikov, ki so prejemali Keppro, in 29, 8% bolnikov, ki so prejemali placebo, imelo neželene učinke, za katere so presodili, da so povezani z zdravljenjem.
The most commonly reported undesirable effect was fatigue.
Najpogosteje opisani neželeni učinek je bila utrujenost.
Undesirable effects reported in clinical studies (adults and children) or from post-marketing experience are listed in the following table per System Organ Class and per frequency.
Neželeni učinki, o katerih so poročali v kliničnih študijah (odrasli in otroci) ali v postmarketinškem obdobju, so navedeni v spodnji tabeli po organskih sistemih in pogostnosti.
For clinical trials, the frequency is defined as follows: very common (≥ 1/ 10); common (≥ 1/ 100, < 1/ 10); uncommon (≥ 1/ 1,000, < 1/ 100); rare (≥ 1/ 10,000, < 1/ 1,000); very rare (< 1/ 10,000), including isolated reports.
(≥1/ 1. 000, < 1/ 100); redki:
Data from post-marketing experience are insufficient to support an estimate of their incidence in the population to be treated.
(≥1/ 10. 000, < 1/ 1. 000); zelo redki:
- General disorders and administration site conditions
(< 1/ 10. 000), vključno s posameznimi primeri.
Very common: asthenia/ fatigue
− Splošne težave in spremembe na mestu aplikacije Zelo pogosti: astenija/ utrujenost
- Nervous system disorders
− Bolezni prebavil Pogosti: bolečina v trebuhu, driska, dispepsija, navzea, bruhanje Postmarketinške izkušnje: pankreatitis
Very common: somnolence Common: amnesia, ataxia, convulsion, dizziness, headache, hyperkinesia, tremor, balance disorder, disturbance in attention, memory impairment.
− Bolezni jeter, žolčnika in žolčevodov Postmarketinške izkušnje: odpoved jeter, hepatitis, nenormalne vrednosti testov jetrnih funkcij
Post-marketing experience: paraesthesia
− Presnovne in prehranske motnje Pogosti: anoreksija, povečanje telesne mase.
6
6 Postmarketinške izkušnje: zmanjšanje telesne mase
- Metabolism and nutrition disorders
− Ušesne bolezni, vključno z motnjami labirinta Pogosti: vrtoglavica
Post-marketing experience: weight loss
− Očesne bolezni Pogosti: diplopija, zamegljen vid
- Musculoskeletal and connective tissue disorders
− Bolezni mišično- skeletnega sistema in vezivne tkiva Pogosti: mialgija
- Infections and infestations
− Poškodbe, zastrupitve in zapleti pri posegih Pogosti: naključna poškodba
- Respiratory, thoracic and mediastinal disorders
− Infekcijske in parazitske bolezni Pogosti: okužba, nazofaringitis
- Skin and subcutaneous tissue disorders
− Bolezni dihal, prsnega koša in mediastinalnega prostora Pogosti: okrepljen kašelj
Common: rash, eczema, pruritus Post-marketing experience: alopecia: in several cases, recovery was observed when Keppra was discontinued.
− Bolezni kože in podkožja Pogosti: izpuščaj, ekcem, pruritus Postmarketinške izkušnje: alopecija: v nekaterih primerih so po prekinitvi zdravljenja s Keppro opazili izboljšanje.
Common: thrombocytopenia Post-marketing experience: leukopenia, neutropenia, pancytopenia (with bone marrow suppression identified in some of the cases)
− Bolezni krvi in limfatičnega sistema Pogosti: trombocitopenija Postmarketinške izkušnje: levkopenija, nevtropenija, pancitopenija (s supresijo kostnega mozga v posameznih primerih)
Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with Keppra overdoses.
Pri prevelikem odmerjanju Keppre so opažali zaspanost, agitiranost, agresivnost, zmanjšano stopnjo zavesti, depresijo dihanja in komo.
7 After an acute overdose, the stomach may be emptied by gastric lavage or by induction of emesis.
Po akutnem prevelikem odmerjanju lahko želodec izpraznimo z izpiranjem ali sprožitvijo bruhanja.
The dialyser extraction efficiency is 60% for levetiracetam and 74% for the primary metabolite.
Učinkovitost dializne ekstrakcije levetiracetama je 60%, primarnega presnovka pa 74%.
Pharmacotherapeutic group: antiepileptics, ATC code:
Farmakoterapevtska skupina: drugi antiepileptiki, Oznaka ATC:
The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of α -ethyl-2-oxo-1- pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances.
Zdravilna učinkovina levetiracetam je pirolidonski derivat (S- enantiomer α- etil- 2- okso- 1 - pirolidinacetamida), ki kemično ni podoben drugim protiepileptičnim učinkovinam.
The mechanism of action of levetiracetam still remains to be fully elucidated but appears to be different from the mechanisms of current antiepileptic medicinal products.
7 Mehanizem delovanja levetiracetama še vedno ni popolnoma pojasnjen, vendar kaže, da je drugačen od mehanizmov drugih protiepileptičnih zdravil.
In vitro studies show that levetiracetam affects intraneuronal Ca2+ levels by partial inhibition of N- type Ca2+ currents and by reducing the release of Ca2+ from intraneuronal stores.
In vitro študije so pokazale, da levetiracetam vpliva na nivo Ca2+ znotraj nevrona preko delne inhibicije N- tipa Ca2+ kanalov in znižanjem sproščanja Ca2+ iz zalog znotraj nevrona.